{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT03019588",
      "orgStudyIdInfo": {
        "id": "KEYNOTE-063",
        "type": null,
        "link": null
      },
      "secondaryIdInfos": [],
      "organization": {
        "fullName": "Merck Sharp & Dohme Corp.",
        "class": "INDUSTRY"
      },
      "briefTitle": "Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer in Asian patients",
      "officialTitle": "Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients",
      "acronym": "KEYNOTE-063"
    },
    "descriptionModule": null,
    "conditionsModule": null,
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "patientRegistry": false,
      "targetDuration": null,
      "phases": [
        "PHASE3"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "interventionModelDescription": "Patients were randomly assigned 1:1 to receive 200 mg of pembrolizumab intravenously every 3 weeks or 80 mg/m² of paclitaxel intravenously on days 1, 8, and 15 of each 4-week cycle. Patients were stratified by time to progression on first-line therapy (<6 vs ≥6 months) and ECOG PS (0 vs 1).",
        "primaryPurpose": "TREATMENT",
        "observationalModel": null,
        "timePerspective": null,
        "maskingInfo": {
          "masking": "NONE",
          "maskingDescription": "This was a randomized, open-label, phase 3 study.",
          "whoMasked": []
        }
      },
      "enrollmentInfo": {
        "count": 94,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Pembrolizumab",
          "type": "EXPERIMENTAL",
          "description": "Patients received 200 mg of pembrolizumab intravenously every 3 weeks for up to 35 cycles (approximately 2 years) or until disease progression, intolerable toxicity, investigator decision, or patient withdrawal of consent.",
          "interventionNames": [
            "DRUG: Pembrolizumab"
          ]
        },
        {
          "label": "Paclitaxel",
          "type": "ACTIVE_COMPARATOR",
          "description": "Patients received 80 mg/m² of paclitaxel intravenously on days 1, 8, and 15 of each 4-week cycle until disease progression, intolerable toxicity, investigator decision, or patient withdrawal of consent.",
          "interventionNames": [
            "DRUG: Paclitaxel"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Pembrolizumab",
          "description": "200 mg administered intravenously every 3 weeks for up to 35 cycles (approximately 2 years)",
          "armGroupLabels": [
            "Pembrolizumab"
          ]
        },
        {
          "type": "DRUG",
          "name": "Paclitaxel",
          "description": "80 mg/m² administered intravenously on days 1, 8, and 15 of each 4-week cycle",
          "armGroupLabels": [
            "Paclitaxel"
          ]
        }
      ]
    },
    "outcomesModule": null,
    "eligibilityModule": null
  }
}